社区眼健康管理及中西医结合综合疗法效果评价

注册号:

Registration number:

ITMCTR2025000798

最近更新日期:

Date of Last Refreshed on:

2025-04-22

注册时间:

Date of Registration:

2025-04-22

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

社区眼健康管理及中西医结合综合疗法效果评价

Public title:

Community eye health management and the effectiveness of integrated traditional Chinese and Western medicine therapy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

社区眼健康管理及中西医结合综合疗法效果评价

Scientific title:

Community eye health management and the effectiveness of integrated traditional Chinese and Western medicine therapy

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王青夏

研究负责人:

马晓昀

Applicant:

QingXia Wang

Study leader:

XiaoYun Ma

申请注册联系人电话:

Applicant telephone:

+8618716677114

研究负责人电话:

Study leader's telephone:

17621942480

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

910605425@qq.com

研究负责人电子邮件:

Study leader's E-mail:

xia7114@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市浦东新区周浦镇周园路1500号

研究负责人通讯地址:

上海市浦东新区周浦镇周园路1500号

Applicant address:

No.1500 Zhouyuan Road Zhoupu Town Pudong New District

Study leader's address:

No.1500 Zhouyuan Road Zhoupu Town Pudong New District

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市浦东新区周浦医院

Applicant's institution:

Zhoupu Hospital Pudong New District Shanghai

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2023-C-189-E01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

上海市浦东新区周浦医院伦理审查委员会

Name of the ethic committee:

Medical Ethics Review Committee of Zhoupu Hospital Pudong New Area Shanghai

伦理委员会批准日期:

Date of approved by ethic committee:

2023/10/3 0:00:00

伦理委员会联系人:

顾蓁

Contact Name of the ethic committee:

Zhen Gu

伦理委员会联系地址:

上海市浦东新区周浦镇周园路1500号

Contact Address of the ethic committee:

No.1500 Zhouyuan Road Zhoupu Town Pudong New District

伦理委员会联系人电话:

Contact phone of the ethic committee:

021-68135086

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zpyykjk@126.com

研究实施负责(组长)单位:

上海市浦东新区周浦医院

Primary sponsor:

Zhoupu Hospital Pudong New District Shanghai

研究实施负责(组长)单位地址:

上海市浦东新区周浦镇周园路1500号

Primary sponsor's address:

No.1500 Zhouyuan Road Zhoupu Town Pudong New District

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

上海/上海市/浦东新区

Country:

China

Province:

shanghai

City:

Shanghai

单位(医院):

上海市浦东新区周浦医院

具体地址:

上海市浦东新区周浦镇周园路1500号

Institution
hospital:

Zhoupu Hospital Pudong New District Shanghai

Address:

No.1500 Zhouyuan Road Zhoupu Town Pudong New District

经费或物资来源:

上海市中西医结合学会社区医学专委会“社区医学与健康管理科研课题研究”专项基金重点项目(2023SQ03)

Source(s) of funding:

Community Medicine and Health Management, and Evaluation of Integrated Chinese and Western Medicine Treatment (2023SQ03).

研究疾病:

近视

研究疾病代码:

Target disease:

myopia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

探讨中医适宜技术耳穴压丸对儿童近视防控的作用。

Objectives of Study:

To explore the effect of auricular pressure pills on the prevention and control of myopia in children.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

① 6~13岁儿童; ② 等效球镜<-0.5D ; ③ 散光<1.5D;屈光参差<1.5D; ④ 无斜视、弱视或其他任何眼病; ⑤ 自愿参加试验,监护人签订知情同意书。

Inclusion criteria

① 6 to 13 years old; ② Equivalent spherical lenses<-0.5D ; ③ Astigmatism <1.5D; refractive error <1.5D; ④ No strabismus amblyopia or any other eye diseases; ⑤ Participate in the test voluntarily and the guardian signs the informed consent form.

排除标准:

① 影响眼部屈光状态的眼部手术史及外伤史; ② 有早产史,影响眼健康的全身疾病或精神疾病者; ③ 1个月内使用过光学干预或药物干预等治疗方式。

Exclusion criteria:

① History of eye surgery and trauma affecting the refractive state of the eye; ② History of preterm labor systemic diseases or mental illnesses that affect eye health; ③ Those who have used treatment modalities such as optical intervention or drug intervention within 1 month

研究实施时间:

Study execute time:

From 2024-02-01

To      2025-02-01

征募观察对象时间:

Recruiting time:

From 2024-02-01

To      2024-11-30

干预措施:

Interventions:

组别:

西医光学干预

样本量:

40

Group:

optical intervention

Sample size:

干预措施:

周边离焦框架眼镜

干预措施代码:

Intervention:

Peripheral defocus glasses

Intervention code:

组别:

中医耳穴贴压联合光学干预

样本量:

40

Group:

auricular acupoint compression and optical intervention

Sample size:

干预措施:

耳穴压丸联合周边离焦框架眼镜

干预措施代码:

Intervention:

Auricular pressure pills and peripheral defocus glasses

Intervention code:

样本总量 Total sample size : 80

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

浦东新区

Country:

china

Province:

shanghai

City:

Shanghai

单位(医院):

上海市浦东新区周浦医院(上海健康医学院附属周浦医院)

单位级别:

三乙

Institution/hospital:

Zhoupu Hospital Pudong New District Shanghai

Level of the institution:

3B

测量指标:

Outcomes:

指标中文名:

裸眼视力

指标类型:

次要指标

Outcome:

uncorrected visual acuity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

等效球镜度

指标类型:

主要指标

Outcome:

spherical equivalent

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼轴长度

指标类型:

主要指标

Outcome:

axial length

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

角膜曲率

指标类型:

次要指标

Outcome:

corneal curvature

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 6
Min age years
最大 13
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究负责人根据计算机随机数字表产生的两位数随机数字来作为来诊患者的随机数字,将随机数字按从小到大排列,前一半为远视储备充足组1,后一半为对照组2

Randomization Procedure (please state who generates the random number sequence and by what method):

A two-digit random number generated by the study leader based on a computerized random number table was used as the random number of patients who came to the clinic and the random numbers were arranged from smallest to largest with the first half being the Adequate Reserve for Farsightedness Group 1 and the second half being the control group2

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

预计共享日期为2025年8月,公开平台为临床试验公共管理平台(ResMan),网址 http://www.medresman.org.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The anticipated data‑sharing date is August 2025, and the dataset will be made publicly available on the ResMan Public Management Platform for Clinical Research (http://www.medresman.org.cn/).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质的病例记录表、电子数据采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form Electronic Data Capture

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

2025.12

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

2025.12

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统